TRIM21 and dermatomyositis: Of the seropositive patients (n = 18, 50%), ten (55.5%) presented with DM, divided into four who had positive anti-TIF1ɣ, one with anti-Ro52, one with anti-NXP2, one with anti-Mi2β, and three with combinations of anti-MDA5 + anti-SAE1 + NXP2, anti-TIF1ɣ + anti-Mi2α and anti-Mi2β + anti-Mi2α.